Marketing agreement for Celltech and Pharmacia

Published: 30-Apr-2001


Pharmacia and Celltech have reached an agreement for the co-development and co-promotion of Celltech's proprietary compound CDP 870.

CDP 870 is a tumour necrosis factor alpha inhibitor. TNF-a is a key mediator in certain autoimmune and inflammatory diseases, and CDP 870 is being developed as a new treatment for rheumatoid arthritis and Crohn's disease. Celltech believes it may have potential for other disorders, including congestive heart failure.

Pharmacia will have exclusive worldwide development and marketing rights, and Celltech will have some limited co-promotion rights.

You may also like